15-Year watch begins for gene therapy recipients
NCT ID NCT06882317
First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 24 times
Summary
This study follows 40 people who have already received CLBR001, a gene therapy using a lentiviral vector. Researchers will monitor them for 15 years to check for any delayed side effects or safety concerns. The goal is to understand the long-term risks of this treatment, not to test a new therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG-TERM FOLLOW-UP are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Indianapolis, Indiana, 46202, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
Virtual Research Group- Premier Research
Morrisville, North Carolina, 27560, United States
Conditions
Explore the condition pages connected to this study.